Abstract: The present invention provides methods and kits for the diagnosis of schizophrenia, which employ mitochondrial complex I as a peripheral biological marker for schizophrenia. In an embodiment of the invention, the present invention provides a method for diagnosing schizophrenia in a subject by determining the level of m-RNA or protein mitochondrial complex I subunits and its activity by determining the cellular basal respiration through complex I enzyme.

Abstract: The present invention provides methods and kits for the diagnosis of schizophrenia, which employ mitochondrial complex I as a peripheral biological marker for schizophrenia. In an embodiment of the invention, the present invention provides a method for diagnosing schizophrenia in a subject by determining the level of m-RNA or protein mitochondrial complex I subunits and its activity by determining the cellular basal respiration through complex I enzyme.

Abstract: The present invention provides methods and kits for the diagnosis of schizophrenia, which employ mitochondrial complex I as a peripheral biological marker for schizophrenia. In one embodiment, the present invention provides a method for diagnosing schizophrenia in a subject by determining the level of activity of a mitochondrial complex I enzyme in a sample obtained from the subject, and comparing the level of activity in the sample with a normative value of mitochondrial complex I enzyme activity, wherein an altered level of activity of mitochondrial complex I enzyme in the sample compared with the normative value is indicative of the subject having schizophrenia.

Abstract: Use of a compound of formula (I), wherein R1 is H or hydrocarbyl; R2 is a hydrophobic radical; R3 is 3-(C2-C6)acyl-4-hydroxyphenyl, 3-hydroxyimino (C2-C6)-alkyl-4-hydroxyphenyl, or COOZ, wherein Z is H, (C1-C6) alkyl, aryl, aryl or ar(C1-C6) alkyl; and n is 1-20; and of a compound of formula (II), wherein R4 is (C1-C6) alkyl, cyano (C1-C6) alkyl, (C1-C6) alkoxy (C1-C6) alkyl or —CH2NR7R8, wherein R7 and R8, the same or different, is each H or (C1-C6) alkyl, or together with the N atom form a saturated or unsaturated 5-7 membered ring optionally containing a further heteroatom selected from N, O or S, the further N atom being optionally substituted, and either R5 is H and R6 is (C2-C6) acyl or hydroxyimino (C2-C6) alkyl, or R5 and R6 together with the phenyl ring form a quinoline, a 1,2,3,4-tetrahydroquinoline or a perhydroquinoline ring, for the preparation of pharmaceutical compositions for the treatment of Parkinson's disease or stroke.

Abstract: The present invention provides methods and kits for the diagnosis of schizophrenia, which employ mitochondrial complex I as a peripheral biological marker for schizophrenia. In one embodiment, the present invention provides a method for diagnosing schizophrenia in a subject by determining the level of activity of a mitochondrial complex I enzyme in a sample obtained from the subject, and comparing the level of activity in the sample with a normative value of mitochondrial complex I enzyme activity, wherein an altered level of activity of mitochondrial complex I enzyme in the sample compared with the normative value is indicative of the subject having schizophrenia.